Monitoring advanced prostate cancer

Survival and response to treatment in advanced prostate cancer can be predicted by the number of circulating tumour cells (CTCs), a study has shown. Researchers assessed CTC number before and after treatment, changes in PSA and baseline lactate dehydrogenase (LDH) in 164 patients receiving first-line chemotherapy. Before treatment, high LDH (HR 6.44), CTC count (1.58) and PSA titre (1.26) were associated with a high risk of death. Post-treatment, assessed at four, eight and 12 weeks, changes in CTC number were strongly associated with risk, but changes in PSA were only weakly associated.

Scher HI, Jia X, de Bono JS et al. Lancet Oncol 2009; doi:10.1016/S1470-2045(08)70340-1.

Originally published in the March 2009 edition of MIMS Oncology & Palliative Care.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs